|
Avaliação DCF do Grupo Biopharma PLC (MREO)
GB | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Mereo BioPharma Group plc (MREO) Bundle
Procurando avaliar o valor intrínseco do grupo mereo biofarma plc? Nossa calculadora DCF (MREO) integra dados do mundo real com recursos abrangentes de personalização, permitindo refinar suas previsões e aprimorar suas opções de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -.1 | .4 | 36.5 | 1.5 | 10.0 | 10.1 | 10.2 | 10.3 | 10.4 | 10.5 |
| Revenue Growth, % | 0 | -422.13 | 9178.37 | -95.87 | 563.57 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 |
| EBITDA | -37.6 | -37.5 | -5.0 | -42.1 | -26.1 | -4.3 | -4.4 | -4.4 | -4.5 | -4.5 |
| EBITDA, % | 30789.34 | -9548.35 | -13.72 | -2791.11 | -260.56 | -42.74 | -42.74 | -42.74 | -42.74 | -42.74 |
| Depreciation | 2.0 | .0 | .9 | 1.5 | 1.1 | .5 | .5 | .5 | .5 | .5 |
| Depreciation, % | -1601.64 | 11.2 | 2.38 | 100 | 10.61 | 4.84 | 4.84 | 4.84 | 4.84 | 4.84 |
| EBIT | -39.5 | -37.6 | -5.9 | -43.6 | -27.1 | -4.4 | -4.4 | -4.5 | -4.5 | -4.5 |
| EBIT, % | 32390.98 | -9559.54 | -16.1 | -2891.11 | -271.17 | -43.22 | -43.22 | -43.22 | -43.22 | -43.22 |
| Total Cash | 16.3 | 23.5 | 94.3 | 56.3 | 57.4 | 6.1 | 6.1 | 6.2 | 6.3 | 6.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1.0 | 1.4 | 2.7 | 3.7 | 4.9 | 4.9 | 5.0 | 5.0 | 5.1 |
| Account Receivables, % | 0 | 258.52 | 3.89 | 182.35 | 37.32 | 48.24 | 48.24 | 48.24 | 48.24 | 48.24 |
| Inventories | -12.0 | -4.6 | -1.8 | -2.7 | .0 | -2.1 | -2.1 | -2.2 | -2.2 | -2.2 |
| Inventories, % | 9817.21 | -1180.15 | -4.99 | -177.31 | 0 | -21 | -21 | -21 | -21 | -21 |
| Accounts Payable | 5.9 | 2.9 | 2.3 | 3.5 | 2.3 | 2.6 | 2.6 | 2.7 | 2.7 | 2.7 |
| Accounts Payable, % | -4820.1 | 747.09 | 6.27 | 231.72 | 23.46 | 25.95 | 25.95 | 25.95 | 25.95 | 25.95 |
| Capital Expenditure | .0 | .0 | -.5 | .0 | -.4 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | 17.21 | -4.07 | -1.47 | -0.66357 | -4.19 | -2.08 | -2.08 | -2.08 | -2.08 | -2.08 |
| Tax Rate, % | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
| EBITAT | -33.5 | -36.9 | -5.2 | -41.3 | -26.6 | -4.1 | -4.1 | -4.1 | -4.2 | -4.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -13.7 | -48.2 | -8.8 | -39.1 | -30.8 | -2.5 | -3.8 | -3.9 | -3.9 | -3.9 |
| WACC, % | 8.18 | 8.21 | 8.19 | 8.2 | 8.21 | 8.2 | 8.2 | 8.2 | 8.2 | 8.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -14.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4 | |||||||||
| Terminal Value | -65 | |||||||||
| Present Terminal Value | -44 | |||||||||
| Enterprise Value | -58 | |||||||||
| Net Debt | -51 | |||||||||
| Equity Value | -6 | |||||||||
| Diluted Shares Outstanding, MM | 659 | |||||||||
| Equity Value Per Share | -0.01 |
What You Will Get
- Real Mereo BioPharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Mereo BioPharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- 🔍 Real-Life MREO Financials: Pre-filled historical and projected data for Mereo BioPharma Group plc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Mereo’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Mereo’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-filled Excel file containing Mereo BioPharma Group plc’s (MREO) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose This Calculator for Mereo BioPharma Group plc (MREO)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Monitor immediate changes in Mereo BioPharma’s valuation as you tweak inputs.
- Pre-Configured Data: Comes pre-loaded with Mereo BioPharma’s latest financial metrics for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts to make well-informed choices.
Who Should Use Mereo BioPharma Group plc (MREO)?
- Investors: Gain insights into innovative biopharmaceutical developments to make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to streamline research and analysis of Mereo BioPharma's market position.
- Consultants: Easily modify reports and presentations to showcase Mereo BioPharma's strategic initiatives for clients.
- Biotech Enthusiasts: Enhance your knowledge of drug development processes and industry trends through real-life case studies.
- Educators and Students: Leverage this information as a valuable resource for coursework in biotechnology and finance.
What the Template Contains
- Pre-Filled DCF Model: Mereo BioPharma Group plc’s (MREO) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital tailored for Mereo BioPharma Group plc.
- Financial Ratios: Assess Mereo BioPharma Group plc’s profitability, leverage, and efficiency metrics.
- Editable Inputs: Modify assumptions such as growth, margins, and CAPEX to suit your analyses.
- Financial Statements: Annual and quarterly reports to facilitate in-depth examination.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.